SEC Form 10-Q filed by Bio-Techne Corp
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2024 | $85.00 | Buy → Neutral | Citigroup |
| 2/8/2024 | $80.00 | Sector Outperform | Scotiabank |
| 2/2/2024 | $65.00 | Buy → Hold | Stifel |
| 12/7/2023 | $80.00 | Buy | UBS |
| 8/28/2023 | Outperform | William Blair | |
| 1/10/2023 | $90.00 | Underweight → Equal Weight | Wells Fargo |
| 12/14/2022 | $100.00 | Buy | Deutsche Bank |
| 12/12/2022 | $81.25 → $100.00 | Neutral → Buy | Citigroup |
SC 13G - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
10-Q - BIO-TECHNE Corp (0000842023) (Filer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
ST. PAUL, Minn., Jan. 21, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been awarded a $300,000 G-Rex® Grant. The G-Rex® Grant will support expeditious process development and commercial readiness of BCB-276, BrainChild Bio's lead autologous CAR-T therapy for the treatment of diffuse intrinsic pontine glioma (DIPG), an incurable type of pediatric brain tumor. BrainChild Bio plans to advance BCB-276 into a multi-center Phase 2 pivotal clinical trial in 2025 for the treatment of children and young adults with DIPG. "G-Rex has been an essential element of our clinical CAR-T manufact
MINNEAPOLIS, Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, February 5, 2025, at 8:00 a.m. CST to review its second quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 5, 2025 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13751305 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers)
MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ:TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using advanced Artificial Intelligence (AI) based design platforms and protein evolutionary workflows. This expanded portfolio from Bio-Techne's R&D Systems brand includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available both for research use only (RUO) and made under good manufacturing processes (GMP) for therapeutic development), as well as Wnt/RSPO1 Agonist, Wnt/RSPO2 Agonist, and Wnt/RSPO3 Agonist proteins. These innovative recombinant proteins are designed and engineered to
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D
MINNEAPOLIS, Jan. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3, 2023. Mr. Bohnen succeeds Brenda Furlow, who will be retiring from the Company after serving as Executive Vice President and General Counsel for the past nine years. Brenda has been and will continue to provide transition support until her March 3, 2023, retirement and will serve in a consulting capacity for special projects going forward. Mr. Bohnen has over 20 years of experience as a senior legal advisor, including serving as Bio-Techne's Associate General Counsel since 2019. During his tenure at Bio-T
MINNEAPOLIS, Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, February 5, 2025, at 8:00 a.m. CST to review its second quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 5, 2025 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13751305 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers)
WEST SACRAMENTO, Calif., Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ:TECH). GeminiBio has a 39-year history of supporting FBS customers. With this agreement, GeminiBio builds on these capabilities, by securing the manufacturing and global sales r
MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights First quarter organic revenue increased by 4% (5% reported) to $289.5 million. GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Delivered adjusted EPS of $0.42 compared to $0.41 one year ago. Continued adoption and utilization across the Diagnostics & Spatial Biology ("DSS"), formerly Diagnostics & Genomics, portfolio led to 14% organic segment growth (14% reported). Continued uptake of our cell and gene therapy workflow solutions, including strong growth in our GMP reagent offeri
Citigroup downgraded Bio-Techne from Buy to Neutral and set a new price target of $85.00
Scotiabank initiated coverage of Bio-Techne with a rating of Sector Outperform and set a new price target of $80.00
Stifel downgraded Bio-Techne from Buy to Hold and set a new price target of $65.00